Abstract
Stereotactic body radiation therapy (SBRT) has emerged as the treatment of choice for medically inoperable stage I non-small cell lung cancer (NSCLC). At the same time, distinct genetic sub-groups of NSCLC have been defined by mutations in oncogenes such as K-ras. In this retrospective study, we compare outcomes after lung SBRT in patients (pts) with K-ras mutant (K-ras mut+) NSCLC versus pts with wild-type or unknown K-ras status (K-ras wt/unk).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
